- Conditions
- Thrombotic Thrombocytopenic Purpura
- Interventions
- Danazol
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Purpura, Thrombocytopaenic, Idiopathic
- Interventions
- eltrombopag, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Orange, California • Jacksonville, Florida + 14 more
- Conditions
- Immune Thrombocytopenia
- Interventions
- SKI-O-703, Placebo oral tablet
- Drug
- Lead sponsor
- Oscotec Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Durham, North Carolina • Greenville, North Carolina + 1 more
- Conditions
- Purpura, Thrombocytopaenic, Idiopathic
- Interventions
- eltrombopag
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2007
- U.S. locations
- 2
- States / cities
- Gainesville, Florida • Orlando, Florida
- Conditions
- Immune Thrombocytopenia
- Interventions
- PRTX-100
- Drug
- Lead sponsor
- Protalex, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Boston, Massachusetts • Farmington Hills, Michigan + 3 more
- Conditions
- Immune Thrombocytopenic Purpura
- Interventions
- BMS-986004 75 mg IV, BMS-986004 225 mg IV, BMS-986004 675 mg IV, BMS-986004 1500 mg IV
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 3 more
- Conditions
- Purpura, Thrombocytopenic, Idiopathic
- Interventions
- Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified
- Drug
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Thrombotic Thrombocytopenic Purpura (TTP)
- Interventions
- TAK-755
- Biological
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 0 Years to 70 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Buffalo, New York • Durham, North Carolina + 2 more
- Conditions
- Primary Immune Thrombocytopenia (ITP)
- Interventions
- Efgartigimod IV, Placebo IV
- Biological · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Los Angeles, California • Oceanside, California + 15 more
- Conditions
- Thrombocytopenia in Pediatric Subjects With Immune Idiopathic Thrombocytopenic Purpura ITP
- Interventions
- Romiplostim
- Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 1 Year and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 24
- States / cities
- Orange, California • San Diego, California • Washington D.C., District of Columbia + 20 more
- Conditions
- Immune-mediated Thrombotic Thrombocytopenic Purpura
- Interventions
- efgartigimod
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Idiopathic Thrombocytopenic Purpura
- Interventions
- Romiplostim
- Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 8
- States / cities
- Anaheim, California • Orange, California • Boynton Beach, Florida + 5 more
- Conditions
- Immune Thrombocytopenia (ITP), Cold Agglutinin Disease (CAD)
- Interventions
- Iptacopan
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Skin Health, Skin Aging of Face and Hands, Healthy, Ecchymosis
- Interventions
- Cyruta Plus: A Whole-Food Based Vitamin C supplement containing organic buckwheat (aerial parts) juice powder, organic buckwheat flour, bovine adrenal Cytosol™ extract, oat flour, honey, ascorbic acid, Low Dose Vitamin C, High Dose Vitamin C
- Dietary Supplement
- Lead sponsor
- Standard Process Inc.
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Kannapolis, North Carolina
- Conditions
- Chronic Idiopathic Thrombocytopenic Purpura, Purpura, Thrombocytopenic, Idiopathic
- Interventions
- Placebo, Avatrombopag tablets
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 25
- States / cities
- Anaheim, California • Bakersfield, California • Concord, California + 21 more
- Conditions
- Primary Immune Thrombocytopenia
- Interventions
- efgartigimod, Placebo
- Biological · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 9
- States / cities
- Tucson, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 6 more
- Conditions
- Primary Immune Thrombocytopenia
- Interventions
- PF-06835375
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Greenville, North Carolina
- Conditions
- ITP, Immune Thrombocytopenia
- Interventions
- Fostamatinib
- Drug
- Lead sponsor
- Rigel Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 14
- States / cities
- Tamarac, Florida • Springfield, Illinois • Kansas City, Kansas + 10 more
- Conditions
- Immune Thrombocytopenic Purpura (ITP)
- Interventions
- Mezagitamab, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 18
- States / cities
- Los Angeles, California • Denver, Colorado • Washington D.C., District of Columbia + 14 more
- Conditions
- Idiopathic Thrombocytopenic Purpura
- Interventions
- Eltrombopag, Avatrombopag, Standard of care
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Watertown, South Dakota
- Conditions
- Chronic Idiopathic Thrombocytopenic Purpura
- Interventions
- Gammaplex, intravenous immunoglobulin
- Biological
- Lead sponsor
- Bio Products Laboratory
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 7
- States / cities
- Orange City, Florida • Chicago, Illinois • Bethesda, Maryland + 4 more
- Conditions
- Immune Thrombocytopenic Purpura
- Interventions
- Fostamatinib Disodium, Placebo
- Drug
- Lead sponsor
- Rigel Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Nyack, New York
- Conditions
- Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia, Immune Thrombocytopenic Purpura
- Interventions
- CTX112
- Biological
- Lead sponsor
- CRISPR Therapeutics AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • Omaha, Nebraska
- Conditions
- Autoimmune Pancytopenia, Autoimmune Lymphoproliferative Syndrome (ALPS), Evans Syndrome, Idiopathic Thrombocytopenic Purpura, Anemia, Hemolytic, Autoimmune, Autoimmune Neutropenia, Lupus Erythematosus, Systemic, Inflammatory Bowel Disease, Rheumatoid Arthritis
- Interventions
- sirolimus
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2016
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania